Real-world treatment patterns and outcomes in chronic lymphocytic leukemia: a multicenter retrospective study in Greece.
Real-world data confirms that newer targeted leukemia drugs improve survival and align with clinical trial benefits across diverse patient populations.
This large multicenter Greek registry study documents the real-world transition in CLL treatment from FCR-based chemoimmunotherapy to BTK and BCL-2 inhibitors between 2010-2024, confirming favorable survival outcomes with targeted agents that align with clinical trial data. The study provides population-level evidence for guideline adoption and confirms second malignancy rates (~6% total) in CLL patients.
What the study was
- Study design
- retrospective_cohort
- Population
- CLL patients across 8 Greek centers, 2010-2024
- Sample size
- 1318
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- Ann Hematol
Why it surfaced
Standard: robust real-world CLL evidence with n=1318 multicenter; confirms targeted agent transition aligning with clinical trial data; score 7 reflects validated but incremental real-world confirmation rather than novel finding; pipeline_priority corrected to STANDARD per score-7 rule.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.